SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001104659-24-058649
Filing Date
2024-05-08
Accepted
2024-05-08 16:01:24
Documents
3
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm2412870d1_sc13ga.htm SC 13G/A 63272
2 EXHIBIT 1 tm2412870d1_ex99-1.htm EX-99.1 26719
3 EXHIBIT 2 tm2412870d1_ex99-2.htm EX-99.2 6181
  Complete submission text file 0001104659-24-058649.txt   97784
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Filed by) CIK: 0001030617 (see all company filings)

Type: SC 13G/A

Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Subject) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91606 | Film No.: 24925725
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)